January 2020

LGC acquires C/D/N Isotopes

LGC has today announced the acquisition of C/D/N Isotopes (CDN), a leading manufacturer and supplier of deuterium-labelled compounds.  The acquisition follows LGC’s recent acquisition of Toronto Research Chemicals (TRC), the leading manufacturer and supplier of analytical standards, which has enjoyed a longstanding trading relationship with CDN.

The acquisition of CDN strengthens LGC’s position in the deuterated compound market and provides an extensive portfolio of products, which are highly complementary with those of LGC’s existing analytical standard and reference material businesses. CDN is well-positioned for growth going forward alongside LGC’s market leading product brands including TRC, Dr Ehrenstorfer™ and Mikromol™.

Euan O’Sullivan, Managing Director, LGC Standards, said, “We are delighted to welcome CDN’s employees to LGC and to add its products to our growing portfolio of stable isotope-labelled compounds. The acquisition will allow us to optimise operations across CDN, TRC and the rest of LGC and we look forward to drawing on CDN’s considerable expertise and know-how as we provide the extended range of compounds to our customers around the world.”

Jim Ounsworth, President, CDN Isotopes, along with fellow co-founders, Yves Nadeau, Production Director and Vincent Guay, Laboratory Director, agreed, saying, “We look forward to growing CDN’s business as part of the LGC Group.  With LGC’s larger distribution network, we expect to be able to reach more customers around the world.  The potential for growth is much greater for CDN as part of LGC.”

CDN was founded in 1993 and has 23 employees. Based in Montreal, Canada, it has a catalogue of over 3,400 compounds. This portfolio covers a range of categories and complex products, such as pharmaceutical and environmental standards, pesticides, steroids, carbohydrates, labelled solvents, fatty acids and amino acids, which are used by a global customer base across the pharmaceutical, medical diagnostic, water treatment and medical research sectors.